Cessatech annonces the issuance of its first US patent covering CT001
Copenhagen, Denmark, 02 November 2021 – Cessatech A/S (“Cessatech” or the “Company”) announces that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11.160.799 to the Company, which is directed to a storage stable pre-filled and ready to use nasal spray device comprising sufentanil and ketamine and a method of treating or preventing pain in a child by use of said device.CT001 is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an